Literature DB >> 21039083

Cardiogenic shock: the role of inflammation.

Alexander Shpektor1.   

Abstract

Cardiogenic shock (CS) is the leading cause of death in patients with acute myocardial infarction (MI) and we badly need new approaches in its treatment. It has been demonstrated that a number of inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α, CRP, soluble adhesion molecules, complement system etc) are elevated in acute MI complicated by CS. Baseline levels of pro- inflammatory cytokines have predictive value for the development of CS and subsequent mortality. The deleterious effects of pro- inflammatory cytokines may be due to excessive nitric oxide production by enzyme named NOS. However in multicenter randomized TRIUMPH study non-selective NOS inhibition was ineffective in the treatment of cardiogenic shock. A challenging subject of future studies will be treatment of CS with specific inhibitors of inducible isoform of NOS. Considering the results of treatment of patients with septic shock it would be reasonable to study the effects of small doses of corticosteroids and hemofiltration in patients with CS and signs of SIRS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039083     DOI: 10.3109/17482941.2010.523705

Source DB:  PubMed          Journal:  Acute Card Care        ISSN: 1748-2941


  14 in total

1.  Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice.

Authors:  Ricky Cheung; Fran Shen; Joseph H Phillips; Mandy J McGeachy; Daniel J Cua; Paul G Heyworth; Robert H Pierce
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

2.  Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β.

Authors:  R Prondzinsky; S Unverzagt; H Lemm; N Wegener; K Heinroth; U Buerke; M Fiedler; J Thiery; J Haerting; K Werdan; M Buerke
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-07-20       Impact factor: 0.840

3.  Shenfu Injection () inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock.

Authors:  Yan-Yan Jin; Hai Gao; Xin-Yong Zhang; Hui Ai; Xiao-Lin Zhu; Jing Wang
Journal:  Chin J Integr Med       Date:  2016-12-27       Impact factor: 1.978

4.  Recurrent thrombosis after mechanical circulatory support.

Authors:  Nadia Aissaoui; Kavus Hakim-Meibodi; Michiel Morshuis; Jan Gummert
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-20

Review 5.  Cancer gene therapy using mesenchymal stem cells.

Authors:  Ryosuke Uchibori; Tomonori Tsukahara; Ken Ohmine; Keiya Ozawa
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

Review 6.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

Review 7.  Nitric oxide in the normal kidney and in patients with diabetic nephropathy.

Authors:  Paolo Tessari
Journal:  J Nephrol       Date:  2014-09-13       Impact factor: 3.902

8.  Persistently elevated osteopontin serum levels predict mortality in critically ill patients.

Authors:  Christoph Roderburg; Fabian Benz; David Vargas Cardenas; Matthias Lutz; Hans-Joerg Hippe; Tom Luedde; Christian Trautwein; Norbert Frey; Alexander Koch; Frank Tacke; Mark Luedde
Journal:  Crit Care       Date:  2015-06-26       Impact factor: 9.097

9.  Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction.

Authors:  René P Andrié; Ulrich M Becher; Ricarda Frommold; Vedat Tiyerili; Jan W Schrickel; Georg Nickenig; Jörg O Schwab
Journal:  Crit Care       Date:  2012-08-13       Impact factor: 9.097

10.  Determination of risk factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention.

Authors:  Rui Wang; Biqi Mei; Xinlong Liao; Xia Lu; Lulu Yan; Man Lin; Yao Zhong; Yili Chen; Tianhui You
Journal:  BMC Cardiovasc Disord       Date:  2017-09-12       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.